DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18–24 months old

Table 2 Summary of pre-booster and post-booster antibody level of tested antibodies^*

Antibody	N = 396	Subjects (%)	95% CI	GMT(Range)
Diphtheria
Pre-booster titer (IU/mL)				0.054 (0.047–0.061)
Anti-D ≥ 0.01^a	295	74.5
Anti-D ≥ 0.1^b	81	20.5	16.8–24.7
Post-booster titer (IU/mL)				0.508 (0.446–0.580)
Anti-D ≥ 0.01^a	394	99.7
Anti-D ≥ 0.1^b	344	87.1	83.4–90.0
Increased antibody titer^c	345	87.1
Seroconversion ^d	98/98	100
Tetanus
Pre-booster titer (IU/mL)				0.187 (0.169–0.206)
Anti-tetanus ≥0.01 ^a	396	100
Anti-tetanus ≥0.1 ^b	286	72.2	67.4–76.2
Post-booster titer (IU/mL)				3.853 (3.531–4.205)
Anti-tetanus ≥0.01 ^a	396	100
Anti-tetanus ≥0.1 ^b	394	95.5	98.2–99.9
Increased antibody titer^c	363	91.7
Pertussis
Pre-booster titer				28.086 (24.791–31.812)
≥ 1/40^a	160	40.4	35.7–45.3
≥ 1/80^b	99	25.0	21.0–29.5
Post-booster titer				639.145 (550.807–741.651)
≥ 1/40^a	378	95.5	92.9–97.1
≥ 1/80^b	367	92.7	89.7–94.9
Increased antibody titer^c	360	90.9
Hepatitis B
Pre-booster titer (mIU/mL)				85.27 (74.199–98.016)
Anti-HBs ≥10	357	90.2	86.8–92.7	85.27 (74.199–98.016)
Post-booster titer (mIU/mL)				5591.13 (4761.02–6564.47)
Anti-HBs ≥10	394	99.5	97.8–98.7	5591.13 (4761.02–6564.47)
Increased antibody titer^c	385	97.2
Seroconversion^d	37/39	94.9
PRP-T (Hib)
Pre-booster titer (μg/mL)				3.399 (3.006–3.844)
Anti-Hib ≥0.15^a	387	97.7
Anti-Hib ≥1.0^b	343	86.6	82.9–89.6
Post-booster titer (μg/mL)				70.226 (61.249–80.501)
Anti-Hib ≥0.15^a	396	100
Anti-Hib ≥1.0^b	394	99.5	98.2–99.9
Increased antibody titer^c	326	82.3
Seroconversion^d	9/9	100

^*Based on per-protocol analysis
^aShort-term protection, ^bLong-term protection, ^cIncreased antibody titer ≥4 times from the pre-booster level, ^dTransition from seronegative to seropositive

ISSN: 1471-2431